Immunotherapy for Advanced Melanoma: 5-Year Survival Data
Key Findings
Five-year overall survival reached 52% with combination immunotherapy vs 34% with monotherapy. Durable responses observed.
Summary
Five-year overall survival reached 52% with combination immunotherapy vs 34% with monotherapy. Durable responses observed.
Study Design
Long-term follow-up of 1,200 patients with unresectable stage III or metastatic melanoma from pivotal trial.
Methods
Patients treated with PD-1 and CTLA-4 inhibitor combination or PD-1 monotherapy. Median follow-up 60 months.
Results
5-year OS: 52% combination vs 34% monotherapy. Complete response: 19% vs 9%. Grade 3-4 events: 59% vs 28%.
Conclusions
Combination immunotherapy provides sustained survival benefit in advanced melanoma despite higher toxicity rates.
Full Abstract
This study examined immunotherapy for advanced melanoma: 5-year survival data in a comprehensive clinical investigation.